Fibrinogen Concentrate Market - Growth, Trends, and Forecast (2020 - 2025)
発行: Mordor Intelligence Pvt Ltd
ページ情報: 英文 117 Pages
フィブリノゲン濃縮製剤の市場規模は、予測期間中に健全なCAGRで成長すると予測されています。市場成長の主な要因は、出血性疾患の有病率の増加と、フィブリノゲン濃縮製剤に関連する承認の数の増加です。英国医師血友病協会（United Kingdom Doctor's Hemophilia Association）の調査によると、2018年、凝固障害のある人は英国で約1万1,089人でした。さらに、2016年に、LFBは製品FibClotを販売するために、欧州で規制当局の承認を受けました。したがって、これらの要因は、フィブリノゲン濃縮製剤の需要を刺激すると予想されます。
The fibrinogen concentrate market is expected to register a healthy CAGR during the forecast period. The major contributing factor for the growth of this market is the increasing prevalence of bleeding disorders and an increase in the number of approvals related to fibrinogen concentrate. According to the study of United Kingdom Doctor's Hemophilia Association, in 2018, people with coagulation defects were around 11,089 in the United Kingdom. Furthermore, in 2016, LFB received its regulatory approval in Europe to market the product, FibClot. Hence, these factors are expected to fuel the demand for fibrinogen concentrate.
Congenital Fibrinogen Deficiency Segment is Expected to Register Significant Growth in the Fibrinogen Concentrate Market
North America is Expected to Hold a Significant Share in the Market and this is Expected Remain the Same in the Forecast Period
North America expected to hold a major market share in the global fibrinogen concentrate market due to the increasing burden of bleeding disorders and rising geriatric population. According to the U.S. Census Bureau, in 2018, people aged 65 and above were accounted to be approximately 52 million. Acquired hemophilia, a rare autoimmune disorder, is quite predominant in the geriatric population. According to the National Organization of Rare Disorders, at least 1-2 people per 1,000,000 are affected by the acquired hemophilia in the United States. Around 50% of the affected population the underlying disorders are difficult to identify. Also, according to the National Hemophilia Foundation, Von Willebrand Disease is one of the common bleeding disorders that affects around 1% of the population every year in the United States. Hence, such factors are affected to drive market growth in the North America region.
Various companies are taking initiatives to improve their presence in the market. In 2019, Octapharma AG received approval for Fibryga, a fibrinogen concentrate, to be marketed in 15 European countries. Few of the companies that are currently dominating the market are LFB, Molecular Innovations Inc., Octapharma AG, CSL Behring, Shanghai RAAS, and Hualan Biological Engineering Inc.